Rationale for individualizing haemophilia care

Benny Sørensen, Günter Auerswald, Gary Benson, Ivo Elezović, Markus Felder, Thierry Lambert, Massimo Morfini, Eduardo Remor, Peter Salaj, Elena Santagostino, Silva Z. Šalek, Rolf Ljung

Research output: Contribution to journalArticle

Abstract

Owing to the heterogeneity in the clinical phenotype of haemophilia A and B, it is now recognized that disease severity (based on factor VIII/IX activity) may no longer be the most appropriate guide for treatment and that a 'one-size-fits-all' approach is unlikely to achieve optimal therapy. Based on the present literature and consensus views of a group of experts in the field, this article highlights key gaps in the understanding of the diverse relationships between bleeding phenotype and factors such as joint health, genetic susceptibility, laboratory parameters, quality of life and management of pain. Early prophylaxis is a potential 'gold standard' therapy and issues surrounding inhibitor development, variations in its clinical use and long-term outcomes are discussed. Comprehensive treatment should be individualized for all patients (including those with mild or moderate haemophilia and carriers). Wherever possible all patients should be given prophylaxis. However, adult patients with a milder haemophilia phenotype may be candidates for ceasing prophylaxis and switching to on-demand treatment. Regardless, all treatment (on-demand and prophylaxis) should be tailored towards both the patient's personal needs and their clinical profile. In addition, as the associations between risk factors (psychosocial, condition-related and treatment-related) and clinical features are unique to each patient, an individualized approach is required to enable patients to alter their behaviour in response to them. The practical methodologies needed to reach this goal of individualized haemophilia care, and the health economic implications of this strategy, are ongoing topics for discussion.

Original languageEnglish
Pages (from-to)849-857
Number of pages9
JournalBlood Coagulation and Fibrinolysis
Volume26
Issue number8
DOIs
Publication statusPublished - 2015

Fingerprint

Hemophilia A
Phenotype
Therapeutics
Hemophilia B
Factor IX
Factor VIII
Pain Management
Genetic Predisposition to Disease
Joints
Economics
Quality of Life
Hemorrhage
Delivery of Health Care
Health

Keywords

  • Haemophilia
  • Health economics
  • Individualized care
  • Inhibitors
  • On-demand
  • Prophylaxis

ASJC Scopus subject areas

  • Hematology

Cite this

Sørensen, B., Auerswald, G., Benson, G., Elezović, I., Felder, M., Lambert, T., ... Ljung, R. (2015). Rationale for individualizing haemophilia care. Blood Coagulation and Fibrinolysis, 26(8), 849-857. https://doi.org/10.1097/MBC.0000000000000225

Rationale for individualizing haemophilia care. / Sørensen, Benny; Auerswald, Günter; Benson, Gary; Elezović, Ivo; Felder, Markus; Lambert, Thierry; Morfini, Massimo; Remor, Eduardo; Salaj, Peter; Santagostino, Elena; Šalek, Silva Z.; Ljung, Rolf.

In: Blood Coagulation and Fibrinolysis, Vol. 26, No. 8, 2015, p. 849-857.

Research output: Contribution to journalArticle

Sørensen, B, Auerswald, G, Benson, G, Elezović, I, Felder, M, Lambert, T, Morfini, M, Remor, E, Salaj, P, Santagostino, E, Šalek, SZ & Ljung, R 2015, 'Rationale for individualizing haemophilia care', Blood Coagulation and Fibrinolysis, vol. 26, no. 8, pp. 849-857. https://doi.org/10.1097/MBC.0000000000000225
Sørensen B, Auerswald G, Benson G, Elezović I, Felder M, Lambert T et al. Rationale for individualizing haemophilia care. Blood Coagulation and Fibrinolysis. 2015;26(8):849-857. https://doi.org/10.1097/MBC.0000000000000225
Sørensen, Benny ; Auerswald, Günter ; Benson, Gary ; Elezović, Ivo ; Felder, Markus ; Lambert, Thierry ; Morfini, Massimo ; Remor, Eduardo ; Salaj, Peter ; Santagostino, Elena ; Šalek, Silva Z. ; Ljung, Rolf. / Rationale for individualizing haemophilia care. In: Blood Coagulation and Fibrinolysis. 2015 ; Vol. 26, No. 8. pp. 849-857.
@article{8f20053073884d09ae8fa3bd8c1d7b92,
title = "Rationale for individualizing haemophilia care",
abstract = "Owing to the heterogeneity in the clinical phenotype of haemophilia A and B, it is now recognized that disease severity (based on factor VIII/IX activity) may no longer be the most appropriate guide for treatment and that a 'one-size-fits-all' approach is unlikely to achieve optimal therapy. Based on the present literature and consensus views of a group of experts in the field, this article highlights key gaps in the understanding of the diverse relationships between bleeding phenotype and factors such as joint health, genetic susceptibility, laboratory parameters, quality of life and management of pain. Early prophylaxis is a potential 'gold standard' therapy and issues surrounding inhibitor development, variations in its clinical use and long-term outcomes are discussed. Comprehensive treatment should be individualized for all patients (including those with mild or moderate haemophilia and carriers). Wherever possible all patients should be given prophylaxis. However, adult patients with a milder haemophilia phenotype may be candidates for ceasing prophylaxis and switching to on-demand treatment. Regardless, all treatment (on-demand and prophylaxis) should be tailored towards both the patient's personal needs and their clinical profile. In addition, as the associations between risk factors (psychosocial, condition-related and treatment-related) and clinical features are unique to each patient, an individualized approach is required to enable patients to alter their behaviour in response to them. The practical methodologies needed to reach this goal of individualized haemophilia care, and the health economic implications of this strategy, are ongoing topics for discussion.",
keywords = "Haemophilia, Health economics, Individualized care, Inhibitors, On-demand, Prophylaxis",
author = "Benny S{\o}rensen and G{\"u}nter Auerswald and Gary Benson and Ivo Elezović and Markus Felder and Thierry Lambert and Massimo Morfini and Eduardo Remor and Peter Salaj and Elena Santagostino and Šalek, {Silva Z.} and Rolf Ljung",
year = "2015",
doi = "10.1097/MBC.0000000000000225",
language = "English",
volume = "26",
pages = "849--857",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Rationale for individualizing haemophilia care

AU - Sørensen, Benny

AU - Auerswald, Günter

AU - Benson, Gary

AU - Elezović, Ivo

AU - Felder, Markus

AU - Lambert, Thierry

AU - Morfini, Massimo

AU - Remor, Eduardo

AU - Salaj, Peter

AU - Santagostino, Elena

AU - Šalek, Silva Z.

AU - Ljung, Rolf

PY - 2015

Y1 - 2015

N2 - Owing to the heterogeneity in the clinical phenotype of haemophilia A and B, it is now recognized that disease severity (based on factor VIII/IX activity) may no longer be the most appropriate guide for treatment and that a 'one-size-fits-all' approach is unlikely to achieve optimal therapy. Based on the present literature and consensus views of a group of experts in the field, this article highlights key gaps in the understanding of the diverse relationships between bleeding phenotype and factors such as joint health, genetic susceptibility, laboratory parameters, quality of life and management of pain. Early prophylaxis is a potential 'gold standard' therapy and issues surrounding inhibitor development, variations in its clinical use and long-term outcomes are discussed. Comprehensive treatment should be individualized for all patients (including those with mild or moderate haemophilia and carriers). Wherever possible all patients should be given prophylaxis. However, adult patients with a milder haemophilia phenotype may be candidates for ceasing prophylaxis and switching to on-demand treatment. Regardless, all treatment (on-demand and prophylaxis) should be tailored towards both the patient's personal needs and their clinical profile. In addition, as the associations between risk factors (psychosocial, condition-related and treatment-related) and clinical features are unique to each patient, an individualized approach is required to enable patients to alter their behaviour in response to them. The practical methodologies needed to reach this goal of individualized haemophilia care, and the health economic implications of this strategy, are ongoing topics for discussion.

AB - Owing to the heterogeneity in the clinical phenotype of haemophilia A and B, it is now recognized that disease severity (based on factor VIII/IX activity) may no longer be the most appropriate guide for treatment and that a 'one-size-fits-all' approach is unlikely to achieve optimal therapy. Based on the present literature and consensus views of a group of experts in the field, this article highlights key gaps in the understanding of the diverse relationships between bleeding phenotype and factors such as joint health, genetic susceptibility, laboratory parameters, quality of life and management of pain. Early prophylaxis is a potential 'gold standard' therapy and issues surrounding inhibitor development, variations in its clinical use and long-term outcomes are discussed. Comprehensive treatment should be individualized for all patients (including those with mild or moderate haemophilia and carriers). Wherever possible all patients should be given prophylaxis. However, adult patients with a milder haemophilia phenotype may be candidates for ceasing prophylaxis and switching to on-demand treatment. Regardless, all treatment (on-demand and prophylaxis) should be tailored towards both the patient's personal needs and their clinical profile. In addition, as the associations between risk factors (psychosocial, condition-related and treatment-related) and clinical features are unique to each patient, an individualized approach is required to enable patients to alter their behaviour in response to them. The practical methodologies needed to reach this goal of individualized haemophilia care, and the health economic implications of this strategy, are ongoing topics for discussion.

KW - Haemophilia

KW - Health economics

KW - Individualized care

KW - Inhibitors

KW - On-demand

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=84947126707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947126707&partnerID=8YFLogxK

U2 - 10.1097/MBC.0000000000000225

DO - 10.1097/MBC.0000000000000225

M3 - Article

C2 - 25396764

AN - SCOPUS:84947126707

VL - 26

SP - 849

EP - 857

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 8

ER -